Quick regression of brain metastases from lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A case report and literature review

Huang,Huaqiong; Zhu,Shuangli; Wang,Shaobin; Li,Wen

doi:10.3892/mco.2016.916

Quick regression of brain metastases from lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A case report and literature review

Authors:
- Huaqiong Huang
- Shuangli Zhu
- Shaobin Wang
- Wen Li
View Affiliations

Affiliations: Department of Respiratory Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: June 2, 2016 https://doi.org/10.3892/mco.2016.916
Pages: 380-382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Brain metastasis (BM) commonly occurs in patients with advanced lung cancer, and is associated with poor prognosis and limited treatment options, particularly for end‑stage patients who are in poor physical and mental state. We herein present a case of lung adenocarcinoma with BM, as revealed by tumor marker and imaging studies. The patient was a 74-year-old woman who was diagnosed with lung adenocarcinoma with several metastatic lesions in the mediastinal lymph nodes, bone and brain. The patient underwent two cycles of chemotherapy, but the cancer recurred with enlarged BM, resulting in confusion and body dysfunction. The patient then received epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI) therapy with icotinib. After approximately 12 h of treatment the symptoms disappeared, and the metastatic lesions in the brain largely regressed in the following months. Our case indicates that the EGFR‑TKI icotinib may provide a rapid and safe approach for emergency situations with BM from lung adenocarcinoma.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Schuette W: Treatment of brain metastases from lung cancer: Chemotherapy. Lung Cancer. 45(Suppl 2): S253–S257. 2004. View Article : Google Scholar : PubMed/NCBI
3	Langer CJ and Mehta MP: Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 23:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
4	Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 322:494–500. 1990. View Article : Google Scholar : PubMed/NCBI
5	Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA and Young B: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 280:1485–1489. 1998. View Article : Google Scholar : PubMed/NCBI
6	Hazard LJ, Jensen RL and Shrieve DC: Role of stereotactic radiosurgery in the treatment of brain metastases. Am J Clin Oncol. 28:403–410. 2005. View Article : Google Scholar : PubMed/NCBI
7	Qin H, Pan F, Li J, Zhang X, Liang H and Ruan Z: Whole brain radiotherapy plus concurrent chemotherapy in non-small cell lung cancer patients with brain metastases: A meta-analysis. PLoS One. 9:e1114752014. View Article : Google Scholar : PubMed/NCBI
8	Hsiung CY, Leung SW, Wang CJ, Lo SK, Chen HC, Sun LM and Fang FM: The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy. J Neurooncol. 36:71–77. 1998. View Article : Google Scholar : PubMed/NCBI
9	Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE and Schmitz PI: Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys. 43:795–803. 1999. View Article : Google Scholar : PubMed/NCBI
10	Armstrong JG, Wronski M, Galicich J, Arbit E, Leibel SA and Burt M: Postoperative radiation for lung cancer metastatic to the brain. J Clin Oncol. 12:2340–2344. 1994.PubMed/NCBI
11	Dinglin XX, Huang Y, Liu H, Zeng YD, Hou X and Chen LK: Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: A single-arm phase II clinical trial. J Neurooncol. 112:461–466. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kataoka K, Uejima T, Niiyama K, Kuroda R, Arita N, Ioku M, Yamada K, Taneda M and Hayakawa T: Long survival after removal of a huge brain tumor which had metastasized from a lung cancer: Case report. Neurological Surgery. 22:339–341. 1994.(In Japanese). PubMed/NCBI
13	Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, et al: National comprehensive cancer network: Non-small cell lung cancer, version 2. 2013. J Natl Compr Canc Netw. 11:645–653; quiz 653. 2013.PubMed/NCBI
14	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L and Villa E: Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol. 15:1042–1047. 2004. View Article : Google Scholar : PubMed/NCBI
16	Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C and Lee JS: Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
17	Jung YH, Han CW, Jung YD, Cho YY and Han DJ: Complete remission of brain metastases in non-small cell lung cancer patients harboring an EGFR mutation treated with tyrosine kinase inhibitor without radiotherapy: A report of 3 cases. Case Rep Oncol. 7:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
18	Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K and Iizasa T: Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 82:282–287. 2013. View Article : Google Scholar : PubMed/NCBI
19	Sun X and Zheng Y: Retreatment with icotinib in a patient with metastatic lung adenocarcinoma. Tumori. 99:e124–e126. 2013.PubMed/NCBI
20	Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P and Wang M: Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 14:188–193. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y and Ma S: Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. World J Surg Oncol. 10:2352012. View Article : Google Scholar : PubMed/NCBI
22	Luo D, Ye X, Hu Z, Peng K, Song Y, Yin X, Zhu G, Ji Q and Peng Y: EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol. 35:2437–2444. 2014. View Article : Google Scholar : PubMed/NCBI